

Arbeitsgruppensitzung Autoimmunbullöse Dermatosen

im Rahmen der ADF-Tagung Innsbruck 2023

Donnerstag, den 23.02.2023 von 9:00 bis 12:30 Uhr

CCB, Universität Innsbruck, Innrain 80/82, 6020 Innsbruck, Österreich, Raum M.01.490

(10 Minuten pro Referat einschl. Diskussion in englischer Sprache!)

9:00

Begrüßung, Technik-Check

Michael Sticherling, Erlangen

Epidermolysis bullosa acquisita (EBA)

9:10

C5aR2 contributes to neutrophil activation and function during the pathogenesis of epidermolysis bullosa acquisita (P094)

D. Seiler, Lübeck

9:20

AIBD-related specific B cells develop under the absence of functional regulatory T cells leading to a pathogenic autoantibody triggering a non-inflammatory form of EBA (P101)

E. Vicari, Heidelberg

Bullous Pemphigoid

9:30

Antibodies against integrin α6/β4 are internalized in vitro but fail to induce a clinical phenotype of mucous membrane pemphigoid in vivo (P057)

S. Patzelt, Lübeck

9:40

Laminin beta 4 is a constituent of the cutaneous basement membrane zone and autoantigen of anti-p200 pemphigoid (P092)

S. Goletz, Lübeck

9:50

Direct binding of complement components to the bullous pemphigoid antigen BP180 may precipitate autoimmune skin disease (P124)

A.Khodr El-Oueyk, Lübeck

10:00

Serration pattern analysis in the diagnostics of pemphigoid diseases"

Antonio Santos, Marburg

10:10

Bullous pemphigoid in patients on immune-checkpoint inhibitors: our experience in Marburg

D. Didona, Marburg

Pemphigus

10:20

Characterization and pharmacological inhibition of a novel adult antibody transfer model of pemphigus vulgaris (P051)
S. Emtenani, Lübeck

10:30

Unravel principles of the biomolecular network in pemphigus vulgaris (P055)
V. Hartmann, Lübeck

10:40

Stimulus-dependent differences of CD24hiCD38hi B cell-derived regulatory cytokines in patients with pemphigus
Alexandra Polakova, Marburg

10:40-11:00 Pause

11:00

High-yield production and cellular implementation of a novel Desmoglein 3 EC5 binding antibody into a keratinocyte based in-vitro skin model (P137)
S. Fink, Jena, Marburg

11:10

NK cells are activated and possess immunoregulatory functions in patients with pemphigus vulgaris (P144)
C. Zimmer, Marburg

11:20

Rituximab is associated with decreased risk of long-term cardiovascular and metabolic outcomes in pemphigus- A propensity-matched global study (P066)
K. Kridin, Lübeck

Autoimmune blistering dermatoses

11:30

Anatomical expression of target antigens in autoimmune blistering dermatoses as markers for lesion formation (P052)
T. Rastegar Lari, Lübeck

11:40

Dipeptidyl-peptidase IV inhibitor-associated autoimmunity: Assessing the risk of 24 autoimmune diseases by a global population-based study (P056)
K. Kridin, Lübeck

11:50

Mortality in eight autoimmune bullous diseases: A global large-scale retrospective cohort study (P068)
K. Boch, Lübeck

12:00

Worsening and new-onset of pemphigus vulgaris and bullous pemphigoid after Covid-19 vaccination
J. Hinterseher, Marburg

12:10 Verschiedenes, Projekte

10:20 Verabschiedung, Ende der Veranstaltung